Bessemer Group
EGRX

Bessemer Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Bessemer Group’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-97
Closed -$3K – 2101
2022
Q4 		$3K Hold
97
– – ﹤0.01% 1746
2022
Q3 		$3K Buy
97
+5
+5% +$183 ﹤0.01% 1884
2022
Q2 		$4K Hold
92
– – ﹤0.01% 1636
2022
Q1 		$5K Buy
+92
New +$4.42K ﹤0.01% 1550
2020
Q3 		– Sell
-30,800
Closed -$1.48M – 1719
2020
Q2 		$1.48M Buy
30,800
+1,300
+4% +$64.9K ﹤0.01% 586
2020
Q1 		$1.36M Buy
29,500
+11,400
+63% +$572K 0.01% 523
2019
Q4 		$1.09M Buy
18,100
+17,000
+1,545% +$1.01M ﹤0.01% 725
2019
Q3 		$62K Buy
+1,100
New +$61.9K ﹤0.01% 1235

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Bessemer Group's EGRX Position: Q1 2023 in Review

Bessemer Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2023, closing a stake of 97 shares — an estimated $3K sold.

Bessemer Group first reported a position in EGRX in Q3 2019 and held it in 8 quarters. The position peaked at $1.48M in Q2 2020. 153 funds tracked by Wall St. Rank hold EGRX as of Q1 2023.

  • Bessemer Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Bessemer Group sold 97 Eagle Pharmaceuticals, Inc. shares in Q1 2023, an estimated $3K.
  • Bessemer Group first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2019 and held it in 8 quarters.
  • Bessemer Group's Eagle Pharmaceuticals, Inc. position peaked at $1.48M in Q2 2020.
  • 153 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2023.

Based on Bessemer Group's 13F filing for Q1 2023, filed 10 May 2023.